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ABSTRACT 
Objective: We explored how investigators of ongoing or planned trials respond to the 
publication of a trial stopped early for benefit addressing a similar question. 
Study Design and Setting: 
We searched multiple databases from the date of publication of the truncated trial 
through August, 2015. Independent reviewers selected trials and extracted data.  
Results: 
We identified 207 trials truncated for early benefit; of which 102 (49%) were followed by 
subsequent trials (262 subsequent trials, median 2 per truncated trial, range 1-13).  
Only 99 (38%) provided a rationale justifying conducting a trial despite prior stopping. 
The top reasons were to address different population or setting (33%); skepticism of 
truncated trials findings because of small sample size (12%), inconsistency with other 
evidence (11%) or increased risk of bias (7%).  We did not identify significant 
associations between subsequent trials and characteristics of truncated ones (risk of 
bias, precision, funding, or rigor of stopping decision).  
Conclusion 
About half of the trials stopped early for benefit were followed by subsequent trials 
addressing a similar question. This suggests that future trialists may have been skeptic 
about the decision to stop prior trials. A more rigorous threshold for stopping early for 
benefit is needed.   
 
Key words: Randomized controlled trials, trials stopped early for benefit, early 
termination of trials, systematic review, methodology, trial design 
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BACKGROUND 
Randomized controlled trials are sometimes stopped early by trialists if one of the 
interventions appears to be associated with a large benefit. Investigators may halt their 
trial to avoid depriving participants in the comparison group of a beneficial treatment, 
and to ensure rapid dissemination of the intervention.(1) Trials stopped early for benefit 
(truncated trials) are usually published in high-impact journals, receive considerable 
attention, and are likely to influence practice.(2) However; truncated trials tend to 
overestimate the magnitude of benefit by approximately up to one third, and 
overestimates can be much greater when sample sizes and number of events are 
modest.(3)    
Further, the majority of published truncated trials fail to adequately report at least one 
important factor regarding the decision to stop early; such as the planned sample size, 
details of interim analyses, whether a stopping rule informed the decision to stop, or 
whether the analysis was adjusted to account for interim monitoring and truncation.(2) 
Misleading overestimates from truncated trials seriously threaten the integrity of 
decisions made by patients and clinicians when they trade off the benefits and harms of 
interventions. Unfortunately, the majority (71%) of systematic reviews that included 
truncated trials did not comment or recognize this possible bias.(4) Simulation studies 
have shown that when trials stopped early for benefit are included in a meta-analysis, 
the pooled effect size and heterogeneity parameters become distorted.(5) Therefore, 
this issue affects the synthesis of evidence and subsequent decision making that 
depends on systematic reviews, such as guidelines. For example, a trial evaluated the 
efficacy of bisoprolol in patients with a positive dobutamine echocardiography 
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undergoing elective vascular surgery. It showed that bisoprolol significantly reduced the 
risk of perioperative myocardial infarction and cardiac death. The trial was stopped early 
because of this large effect.(6) Guidelines in Europe and the U.S. recommended this 
intervention; which was implemented on a large scale.(7) Subsequent trials showed 
markedly different results and demonstrated that the reduction in myocardial infarction 
was not as large as originally demonstrated and that the intervention increased the risk 
of stroke, hypotension and may increase mortality.(7)  
 
The motivation to stop a trial early for benefit should be balanced against the risk 
of disseminating overestimated treatment effect.  It should also be balanced against the 
loss of the opportunity to generate more precise evidence and opportunity to capture 
the effect of treatment on secondary outcomes and outcomes that require longer follow 
up (particularly adverse effects). If stopping a trial early for benefit was the correct 
decision (ie, it would be unethical to continue the trial); then the conduct of subsequent 
trials addressing the same question (subsequent trials) would also be unethical.   
Several justifiable reasons for launching subsequent trials are plausible. First, 
researchers may want to test the intervention in a population or setting that are 
somewhat different from that of a truncated trial. Second, researchers may be skeptic 
about the results of the truncated trials (because the trial was small or at high risk of 
bias). Third, researchers may be interested in knowing the effect of the treatment on 
other outcomes.      
If investigators, the clinical community, and ethics committees sanction 
subsequent trials, it raises serious questions regarding the initial decision to truncate the 
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original trials for benefit.  To explore the incidence of and rationale for subsequent trials, 
we conducted a meta-epidemiological study addressing how often subsequent trials 
were launched or continued after the publication of a truncated trial asking the same or 
similar research question.  
 
METHODS/DESIGN 
The protocol of this study has been published and provides further details.(8) In brief, 
we identified a cohort of 207 truncated trials (published 1970-2007) (2, 3) through 
systematic searches of electronic databases (including MEDLINE, EMBASE, and 
Cochrane), communication with content experts, and manual review of journals.(3) We 
then identified published subsequent trials for each truncated trial. We defined a 
subsequent trial as a subsequent RCT that was launched (i.e., started enrollment) or 
continued enrollment after the truncated trial publication date and addressed a similar 
question (similar population, intervention, comparison and outcome). We only included 
subsequent trials with parallel design that continued follow-up or patient enrollment for 
at least 6 months after truncated trial publication. 
We hypothesized 3 possible reactions of researchers (scenarios) to the publication of a 
truncated trial (figure). Researchers may stop conducting future similar trials (ie, 
truncated trial caused a freezing effect on future research) (a), launch a new trial or 
continue ongoing trials without reaction to truncated trial (b), or modify the protocol of an 
ongoing trial based on results of the truncated trial, or even stop it early (c).  
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
Figure: The possible effects of a trial stopped early for benefit on future research.   
 
 
Literature search 
With input from study investigators, a reference librarian designed and executed 207 
individual search strategies, corresponding to each truncated trial, in MEDLINE, 
EMBASE, Cochrane Library, Web of Science, Scopus, and PsycINFO from the date of 
publication of the truncated trial to August, 2015. These electronic search strategies 
used controlled vocabulary and text words taking into account the characteristics of the 
population involved and the intervention and comparison used.(8) We did not specify 
the outcomes assessed in the truncated trials in the search strategies in order to 
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improve search sensitivity. We augmented our electronic literature searches with hand 
searches of bibliographies of eligible trials and personal communication with content 
experts. 
 
Study selection 
We used online reference management systematic review software (DistillerSR, 
Evidence Partners, Ottawa, Canada; http://systematic-review.net/) to facilitate study 
selection. Pairs of independent reviewers screened the abstracts and then the full text 
version of potential references. Disagreements during abstract screening were included 
for full text screening and disagreements during full text screening were resolved by 
discussion or adjudication by a third reviewer. Agreement among reviewers on study 
selection using the kappa statistic averaged 0.71.   
Data collection 
Reviewers first judged whether patients, interventions, comparators, and outcomes of 
each subsequent trial matched those of the corresponding truncated trial using the 
same criteria established in a previous study (STOPIT- 2, closeness rated on a 4-point 
Likert scale that ranged from 0-3).(3) Trials receiving the lowest similarity score for their 
population or intervention were excluded. Agreement among reviewers averaged 0.70 
on the closeness criteria for patient population, interventions, comparators, and 
outcomes. Using standardized, pilot-tested data extraction forms and a detailed 
instruction manual, pairs of reviewers extracted data from eligible articles independently 
and in duplicate. We extracted subsequent trial characteristics (e.g. dates of enrollment 
and publication), whether a subsequent trial cited the corresponding truncated trial and 
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the rationale for launching or continuing the subsequent trial despite knowing the results 
of the truncated trial. We also extracted data on whether subsequent trials provided a 
sample size calculation, whether sample size calculation was informed by truncated trial 
results, whether a data monitoring committee (DMC) was available, whether truncated 
trial publication led to a change in the subsequent trial protocol (e.g., interim analysis, 
unblinding), and congruence between truncated trial and subsequent trial results with 
respect to the direction of effect and statistical significance.  
Pairs of reviewers assessed risk of bias, independently and in duplicate, of truncated 
trials using items from the Cochrane risk-of-bias tool (9) focusing on allocation 
concealment, blinding, and loss to follow-up. For all phases of data abstraction and risk 
of bias adjudication, reviewers resolved disagreements by discussion or, if necessary, 
by third party adjudication. 
Outcomes of interest and statistical analysis 
The main outcome of interest was the incidence of subsequent trials (proportion of 
truncated trials that were followed by at least one subsequent trial). We conducted 
multiple Poisson and logistic regression analysis to explore the extent to which the 
following a priori established variables  were associated with the decision to conduct a 
subsequent trial:  sample size, number of events, funding source (non-profit/government 
vs. for-profit), allocation concealment (yes vs. no/unclear), patient blinding (yes vs. 
no/unclear), provider blinding (yes vs. no/unclear), presence of a DMC (yes vs. 
no/unclear), the explicit use of a stopping rule (yes vs. no/unclear), and time since 
publication of truncated trial (time from the publication year of truncated trial to 2015). 
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These variables were explored as potential confounders in regression. Poisson 
regression was used when the dependent outcome was the number of subsequent 
trials. Multiple logistic regression was used when the dependent outcome was “no 
subsequent trials published” vs “at least one subsequent trial published”. We conducted 
sensitivity analysis to evaluate truncated trials published later than 1990. We 
hypothesized using this arbitrary date as a cutoff that the reporting and conducting of 
randomized trials have improved over time; particularly after guidelines for reporting 
trials have been implemented by many journals. A two tailed p-value <0.05 was 
regarded as being statistically significant. All statistical analyses were conducted using 
Stata version 14.0 (StataCorp LP, College Station, TX). 
 
RESULTS: 
The literature search yielded 3,217 potential subsequent trials, of which 262 proved 
eligible (figure 1 of the supplement). Overall, reviewers judged subsequent trial 
questions to be similar to truncated trial questions. On a 4-point scale where 3 is most 
similar, similarity or closeness scores of the patient, intervention, comparison and 
outcome averaged 2.25, 2.39, 2.52 and 2.50; respectively. Subsequent trials were 
published on average 4 years after corresponding truncated trials. Table 1 of the 
supplement includes the bibliography of all subsequent trials and related truncated trials 
with year of publication, primary outcome and closeness scores.  
 
Incidence and characteristics of subsequent trials: 
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Overall, 102/207 (49%; 95% confidence interval 42%-56%) of truncated trials were 
followed by at least one subsequent trial addressing a similar question. The majority of 
truncated trials that were followed by subsequent trials had more than one related 
subsequent trial (56/102, 55%); median 2 (range 1-13). The characteristics of truncated 
trials are provided in table 1. The most common clinical areas addressed in these trials 
were cardiology (25%), cancer/malignancy (21%), human immunodeficiency virus 
infections (12%) and critical care (7%). 
 
Table 1 Description of 207 trials stopped early for benefit 
 Truncated trials 
without subsequent 
ones (N=105) 
Truncated trials with 
subsequent ones 
(N=102) 
Mean sample size 965 (range: 8-19,257) 1,330 (range: 12-
22,071) 
Allocation concealment 49.5% 52.9% 
Patient blinding 50.5% 52.9% 
Provider blinding 40.0% 42.2% 
Funding by nonprofit/government sources 28.6% 39.2% 
Presence of DMC 64.8% 68.6 % 
Explicit use of stopping rule 68.6  % 77.5% 
Time since the publication of truncated trial 
(Year) 
15 (range: 8-27) 18 (range: 8-50) 
 
Although the majority of subsequent trials (179/262, 68%) cited the truncated trial and 
most subsequent trials 152 (58%) presented their results in the context of existing 
evidence (i.e., summarized research from other trials in their discussion section), only 
99 (38%) provided a rationale for proceeding with an existing trial or launching a new 
trial in the face of the prior truncated trial.  Reasons for continued investigation included 
indirectness (i.e., to test the intervention in a similar but different population or setting) 
41/99 (41%), the need to collect data on other outcomes (21/99, 21%), or due to 
skepticism regarding the truncated trial results because of small sample size (12/99, 
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12%), increased risk of bias (7/99, 7%), or inconsistency of the results of the truncated 
trial with other evidence (11/99, 11%). The characteristics of subsequent trials are 
provided in table 2. 
Table 2 Description of 262 subsequent trials 
 No. % 
Subsequent trial cited the corresponding truncated trial* 179 68.3% 
         Introduction 140 78.2% 
         Methods 30 16.8% 
         Results 9 5.0% 
         Discussion 148 82.7% 
Rationale for launching or continuing randomization 99 37.8% 
         Subsequent and truncated trials have different questions* 
                  -Different population 
                  -Different Intervention 
                  -Different way to measure the outcome 
41 41.4% 
32 32.3% 
11 11.1% 
2 2.0% 
         Need for more data on other outcomes 21 21.2% 
         Need for more data about harms 0 0.0% 
         Insufficient sample size or number of events in the truncated trial 12 12.1% 
         Truncated trial results are inconsistent with other trials 11 11.1% 
         Risk of bias of the truncated trial 7 7.1% 
Impact of truncated trial publication on conduct of subsequent trial 
         Sample size calculation based on truncated trial 8 3.1% 
         Stopped early 7 2.7% 
         Interim analysis but not stopped 11 4.2% 
Congruence of the results between truncated and subsequent trial 
         In the same direction and both are statistically significant 109 41.6% 
         In the same direction but subsequent trial not significant 88 33.6% 
         In different directions and subsequent trial not significant 29 11.1% 
         In different directions and subsequent trial is significant  2 0.8% 
         Unable to determine because outcomes reported differently 34 13.0% 
* Categories are not mutually exclusive  
 
In general, subsequent trials did not consider results of a truncated trial for sample size 
calculation or analysis plan. Only rarely did the publication of a truncated trial lead to the 
subsequent trial undergoing an interim analysis, breaking randomization codes or 
stopping early (4% of subsequent trials conducted interim analysis and 3% were 
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stopped early). Thirty-nine percent of subsequent trials reported using a DMC and 58% 
presented an explicit sample size calculation. 
The results of subsequent trials were compared to those of truncated trials in terms of 
the outcome used to justify early stopping in truncated trials. The treatment effect 
favored the opposite intervention compared to the truncated trial in 12% of the trials 
(statistically significant in 1%, and non-significant in 11%). 
An illustrative example of a truncated trial and corresponding subsequent trials is 
presented in Table 3. 
Table 3  An illustrative example of a truncated trial and subsequent trials*  
Trial 
 
Sample size 
(number of 
events) 
Effect on 
mortality 
(relative risk and 
95% CI) 
 
Trial rationale 
 
2001: A 
randomized trial 
compared intensive 
insulin therapy to 
conventional 
treatment in 
critically ill surgical 
patients with raised 
serum glucose and 
was stopped early 
for significant 
reduction in 
mortality(10) 
1,548 (35 vs 63) 0.58 (0.38-0.78) Trial was stopped early for benefit 
(index trial) 
2006: A trial 
randomized 
critically ill patients 
in a medical ICU to 
intensive insulin 
therapy or 
conventional 
treatment(11) 
1,200 (144 vs 162) 0.93 (0.81-1.08) Investigators wanted to test the 
intervention in a different 
population (non-surgical patients) 
2008: A trial 
randomized 
critically ill patients 
537 (61 vs 75) 0.95 (0.71-1.27)  Investigators wanted to test the 
intervention in a different 
population (severe sepsis). 
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with sepsis to 
intensive insulin 
therapy or 
conventional 
treatment(12) 
Trial was stopped early at first 
planned safety interim analysis 
due to increased hypoglycemic 
events   
2008: A trial 
randomized 
critically ill patients 
in medical and 
surgical ICUs to 
intensive insulin 
therapy or 
conventional 
treatment(13) 
523 (72 vs 83) 0.84 (0.64-1.09) Investigators considered the 
evidence-base insufficient to 
support intensive insulin therapy 
for critically ill patients  
2009: A trial 
randomized 
critically ill patients 
in medical and 
surgical ICUs to 
intensive insulin 
therapy or 
conventional 
treatment(14) 
6,104 (829 vs 751) 1.11 (1.01- 1.23) Unconvinced with prior evidence, 
investigators wanted to resolve 
uncertainty about benefits and 
harms of intensive insulin therapy 
for critically ill patients.  
Abbreviations: RR, relative risk; CI, confidence interval; ICU, intensive care unit 
*Additional subsequent trials on this topic exist; however, we only describe here trials with more 
than 500 randomized patients.  
 
 
Poisson regression and logistic regression 
Poisson regression and logistic regression demonstrated a statistically significant 
association between the incidence of subsequent trials and the time since the 
publication of the truncated trial suggesting that the longer the time since the truncated 
trial was published, the more subsequent trials were published. We did not find 
statistically significant associations between publication of subsequent trials and all 
other pre-specified explanatory (independent) variables (characteristics of truncated 
trials such as risk of bias, sample size, number of events, funding, presence of a DMC, 
and the explicit use of a stopping rule) (Table 4). 
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Table 4: Association between incidence of subsequent trials and characteristics 
of truncated trials 
Model 1: Poisson regression of the number of subsequent trials 
on truncated trial characteristics 
 Incident Rate 
Ratio 
95% CI p value 
Sample size (per 1,000 
patients) 
1.02 0.96, 1.09 0.55 
Number of events (per 
1,000 events) 
1.25 0.57, 2.73 0.57 
Allocation concealment 0.92 0.54, 1.56 0.76 
Patient blinding 0.98 0.51, 1.87 0.95 
Provider blinding 0.74 0.39, 1.40 0.35 
Funding by 
nonprofit/government 
sources 
0.77 0.50, 1.19 0.24 
Presence of DMC 1.11 0.57, 2.19 0.76 
Existing stop rule 1.81 0.99, 3.31 0.06 
Time since the publication 
of subsequent trial (Year) 
1.07 1.04, 1.10 <0.001 
Model 2: Logistic regression, the publication of any subsequent 
trial on truncated trial characteristics 
subsequent trial Odds Ratio 95% CI p value 
Sample size (per 1,000 
patients) 
1.03 0.90, 1.18  0.68 
Number of events (per 
1,000 events) 
1.38  0.19,10.12 0.75 
Allocation concealment 0.98 0.48, 1.99 0.95 
Patient blinding 0.97 0.33, 2.86 0.96 
Provider blinding 0.79 0.26, 2.36 0.67 
Funding by 
nonprofit/government 
sources 
1.02 0.48, 2.17 0.95 
Presence of DMC 1.68 0.72, 3.88 0.23 
Existing stop rule 1.66 0.74, 3.71 0.22 
Time since the publication 
of subsequent trial 
1.11 1.04, 1.18 <0.01 
 
Sensitivity analysis 
When we excluded truncated trials published earlier than 1990, the conclusions remain 
unchanged. Ninety /190 (47%; 95% confidence interval 40%-55%) of truncated trials were 
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followed by at least one subsequent trial addressing a similar question (supplemental tables 2 
and 3).   
 
DISCUSSION 
Previous empirical studies have demonstrated that the practice of stopping trials early 
for benefit is increasing over time, that many of these trials do not report a rigorous 
approach for the decision to stop, that many exaggerate treatment effects by up to one 
third, and that when sample sizes and number of events are modest, the overestimates 
may be very large.(3) In the current study we found that 49% of truncated trials were 
followed by subsequent trials.  In only a minority of these did investigators provide a 
rationale for randomizing patients despite the prior truncated trial, and in only a minority 
of these did the investigators suggest that findings required replication in an appreciably 
different population or setting.    
The strengths of this study include a systematic and extensive literature search 
performed by an experienced librarian and supported by several methodologists. Tasks 
in this review that required judgment were performed by pairs of reviewers with 
resolution of conflicts by discussion or if necessary by third party adjudication.  For 
subsequent trials we determined authors’ rationale for proceeding, and tested possible 
associations between the decision to proceed and the characteristics of the initial 
truncated trials. Results were robust to sensitivity analysis when older trials were 
excluded. 
One limitation of this study is the difficulty identifying stopped trials in electronic 
databases. The National Library of Medicine added the MeSH term “early termination of 
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clinical trial” in 2010 and EMBASE added the term in 2011; thus, trials published before 
these dates did not have specific indexing terms. In addition, the reliability of these 
terms and consistency in using them have not been formally studied. It is also plausible 
that the grey literature (eg, trial registries and conference proceedings) includes 
additional subsequent trials. Therefore, the current analysis may have underestimated 
the occurrence of subsequent trials published after truncated trials. Adjudication 
regarding similarity between truncated and subsequent trials required judgment, which 
may be flawed.  Our reviewers were, however, all trained clinical epidemiologists. We 
made all judgments in duplicate, and chance-corrected agreement was good. Meta-
epidemiologic research is retrospective, depends on the clarity of reporting in the 
published literature and can be subject to publication bias. Many of the truncated trials 
were published over 20 years ago with different reporting standards, making some 
judgments more difficult than others. 
 
The finding of approximately half of the truncated trials being followed by subsequent 
trials demonstrates that authors of subsequent trials required more evidence than that 
provided by truncated trials, and that funders and ethics committees agreed with the 
necessity for further evidence. For the remaining half of truncated trials, a number of 
possibilities exist. The truncated trial may have provided compelling estimates to the 
extent that no further research was needed on a particular topic. Another possibility, 
which is most concerning, is that truncated trials have caused a “freezing effect” in that 
no further trials addressing the same question could be conducted even if a need was 
perceived.  What would have happened had subsequent trials been conducted in these 
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instances? The results of subsequent trials that were in fact conducted – showed that 
many subsequent trials produced different results from the original truncated trials. 
In 41% of the subsequent trials, authors of subsequent trials cited indirectness of the 
intervention or population as a reason to launch their new trials or continue ongoing 
ones. In other words, they were interested in testing how the intervention might work in 
a population with somewhat different characteristics or test how the intervention would 
work if it was modified (e.g., given at a different dosage).  To the extent that this 
rationale is warranted, it suggests that there may not have been a problem with the 
initial truncation decision. 
 
Other rationales - the small sample size and number of events of truncated trials and 
the need to obtain data on additional outcomes of importance to patients – indicate 
serious problems with the initial truncation decision.(15)   In the 62% of subsequent 
trials in which no rationale was provided, the absence of an explicit hypothesis of 
indirectness suggests the rationale was skepticism that the initial truncated trial results 
were in fact definitive.  
 
The results of this study should impact the development of future trials and the decision-
making process followed by DMCs. The ultimate goal of a DMC in this context should 
be to share benefits of an effective treatment as soon as there is sufficient confidence in 
the magnitude of its effects, on both benefits and harms.(16) Sufficient confidence 
would translate into an ethical mandate to offer the intervention to all patients, and to no 
longer randomize patients to the possibility of not receiving the intervention. Importantly, 
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the current analysis specifically addresses trials stopped early for benefit and not trials 
stopped early for harm (ie safety/adverse effects). Harm accounts for 16% of the 
reasons for stopping trials before their planned completion date,(17) is ethically 
considered an acceptable rationale for halting a trial, and does not lead to concerns 
about exaggerating the estimates of efficacy.  
 
In the subsequent trials we have identified, investigators, funders and ethics committees 
decided that randomizing patients not only continued to be ethical but, in a setting of 
constrained resources was worthy of additional investigation.  The subsequent trial 
investigators, funders, and ethics committees therefore disagreed with the DMCs and 
investigators of the truncated trials that an ethical mandate existed that all patients must 
now receive the putative beneficial intervention.  
 
The current findings, in concert with prior ones (2, 3, 5, 16, 18-20) indicate the need for 
a re-evaluation of the criteria used for stopping early for benefit. Given what we know 
about the risk of overestimating treatment effects and the current perceptions of 
researchers demonstrated in this study, we suggest that DMCs and investigators 
entertaining stopping a trial early for benefit should ask themselves the following 
question: do experts and front-line clinicians agree that the question is definitively 
settled, all patients should now receive the treatment, and further investigation is 
ethically unacceptable?  If these stringent criteria are not met and to ensure obtaining 
the maximal possible information about all relevant outcomes (which itself is an ethical 
mandate), the trial should continue. 
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Key Message: 
About half of the randomized controlled trials stopped early for benefit were followed by 
subsequent trials addressing a similar question 
 
Trialists of subsequent trials may have been skeptic about the decision to stop prior 
trials; thus pursuing their own trials about the same question  
 
There were no characteristics of truncated trials that were associated with, or could 
predict launching subsequent trials 
 
A more rigorous threshold for stopping early for benefit is needed 
